STOCK TITAN

T2 Biosystems Inc - TTOO STOCK NEWS

Welcome to our dedicated news page for T2 Biosystems (Ticker: TTOO), a resource for investors and traders seeking the latest updates and insights on T2 Biosystems.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect T2 Biosystems's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of T2 Biosystems's position in the market.

Rhea-AI Summary
T2 Biosystems, Inc. will report financial results for Q2 2023 on August 7, 2023. The conference call will be held at 4:30 p.m. Eastern Time. Investors can access the live webcast at www.t2biosystems.com and dial 1-888-506-0062 (US/Canada) or 1-973-528-0011 (International) to listen to the conference call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.15%
Tags
conferences earnings
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
T2 Biosystems receives FDA Breakthrough Device designation for Candida auris diagnostic test
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.96%
Tags
none
Rhea-AI Summary
T2 Biosystems announces record sepsis test panel orders and strengthened balance sheet in Q2 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16%
Tags
-
Rhea-AI Summary
T2 Biosystems announces conversion of term loan into common stock and preferred stock, reducing outstanding principal amount by $10 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.16%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.46%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-31.37%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
42.11%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-38.52%
Tags
Rhea-AI Summary
T2 Biosystems initiates process to explore strategic alternatives and announces restructuring plan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-38.52%
Tags
none
T2 Biosystems Inc

Nasdaq:TTOO

TTOO Rankings

TTOO Stock Data

17.31M
4.66M
6.76%
19.28%
7.2%
Small Arms, Ordnance, and Ordnance Accessories Manufacturing
Manufacturing
Link
US
Lexington

About TTOO

t2 biosystems is developing innovative diagnostic products to improve patient health. with two fda-cleared products targeting sepsis – the cause of one out of two hospital deaths - and a range of additional products in development, t2 biosystems is an emerging leader in the field of in vitro diagnostics. our initial development efforts target sepsis, hemostasis, bacteria and lyme disease, which are areas of significant unmet medical need. the company is utilizing its proprietary t2 magnetic resonance platform, or t2mr®, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. at t2 biosystems, we know that our passion to advance the medical diagnostic landscape relies on our ability to attract and retain the very best people in the world – and to encourage them to flourish. we invite you to apply for one of our open positions at www